Molecular treatments to reduce catabolic effects in human meniscus explant models
(2025) In Osteoarthritis and Cartilage Open 7(3).- Abstract
Objectives: 1. To validate catabolic meniscus explant models induced by cytokines: interleukin-6 + interleukin-6 receptor + tumor necrosis factor alpha (IL6/TNF) and oncostatin M + tumor necrosis factor alpha (OSM/TNF). 2. To evaluate three potential anti-catabolic treatments: i) dexamethasone (DEX), ii) a Link-N peptide (Link-N) and iii) a peptide from chondroadherin (CKF). Design: Healthy lateral menisci from deceased donors (n = 6; age = 25–70 years, 4 males, 2 females), were sliced and randomized for experimental groups (combinations of the catabolic models and anti-catabolic treatments) and a control group. Culture media were analyzed, every third day until day 18, by mass spectrometry-based proteomics. Linear mixed... (More)
Objectives: 1. To validate catabolic meniscus explant models induced by cytokines: interleukin-6 + interleukin-6 receptor + tumor necrosis factor alpha (IL6/TNF) and oncostatin M + tumor necrosis factor alpha (OSM/TNF). 2. To evaluate three potential anti-catabolic treatments: i) dexamethasone (DEX), ii) a Link-N peptide (Link-N) and iii) a peptide from chondroadherin (CKF). Design: Healthy lateral menisci from deceased donors (n = 6; age = 25–70 years, 4 males, 2 females), were sliced and randomized for experimental groups (combinations of the catabolic models and anti-catabolic treatments) and a control group. Culture media were analyzed, every third day until day 18, by mass spectrometry-based proteomics. Linear mixed effect models were used to estimate differences in protein abundances between groups. Results: A total of 662 proteins were identified in all menisci. Cytokine-treated meniscus explant models showed increased release of osteoarthritis-related proteins such as matrix metalloproteinases (MMPs). For example, MMP1: IL6/TNF vs. ctrl; log2 fold-change 2.2 95 % confidence interval [1.8, 2.5] and OSM/TNF vs. ctrl; log2 fold-change 2.8 [2.4, 3.1]. There was no treatment effect in explant meniscus with the addition of either Link-N or CKF. Treatment effects were, however, evident with the addition of DEX. For example, MMP1: IL6/TNF + DEX vs. ctrl; log2 fold-change −1.8 [-2.2, −1.4] and OSM/TNF + DEX vs. ctrl; log2 fold-change −0.3 [-0.7, 0.04]. Conclusion: We confirmed that both catabolic models induce changes in osteoarthritis-related proteins. DEX treatment is effective in mitigating the catabolic response in meniscus explant models and may be further explored for its effects in the treatment of meniscus degeneration.
(Less)
- author
- Sjögren, Amanda
LU
; Lindblom, Karin LU ; Turkiewicz, Aleksandra LU ; Englund, Martin LU
and Önnerfjord, Patrik LU
- organization
- publishing date
- 2025-09
- type
- Contribution to journal
- publication status
- published
- subject
- keywords
- Explant model, Human tissue, Meniscus, Osteoarthritis, Proteomics
- in
- Osteoarthritis and Cartilage Open
- volume
- 7
- issue
- 3
- article number
- 100618
- publisher
- Elsevier
- external identifiers
-
- scopus:105004401934
- ISSN
- 2665-9131
- DOI
- 10.1016/j.ocarto.2025.100618
- language
- English
- LU publication?
- yes
- id
- deb60e15-c579-4fd0-b328-c96e9227f257
- date added to LUP
- 2025-07-17 09:56:44
- date last changed
- 2025-07-17 09:57:30
@article{deb60e15-c579-4fd0-b328-c96e9227f257, abstract = {{<p>Objectives: 1. To validate catabolic meniscus explant models induced by cytokines: interleukin-6 + interleukin-6 receptor + tumor necrosis factor alpha (IL6/TNF) and oncostatin M + tumor necrosis factor alpha (OSM/TNF). 2. To evaluate three potential anti-catabolic treatments: i) dexamethasone (DEX), ii) a Link-N peptide (Link-N) and iii) a peptide from chondroadherin (CKF). Design: Healthy lateral menisci from deceased donors (n = 6; age = 25–70 years, 4 males, 2 females), were sliced and randomized for experimental groups (combinations of the catabolic models and anti-catabolic treatments) and a control group. Culture media were analyzed, every third day until day 18, by mass spectrometry-based proteomics. Linear mixed effect models were used to estimate differences in protein abundances between groups. Results: A total of 662 proteins were identified in all menisci. Cytokine-treated meniscus explant models showed increased release of osteoarthritis-related proteins such as matrix metalloproteinases (MMPs). For example, MMP1: IL6/TNF vs. ctrl; log2 fold-change 2.2 95 % confidence interval [1.8, 2.5] and OSM/TNF vs. ctrl; log2 fold-change 2.8 [2.4, 3.1]. There was no treatment effect in explant meniscus with the addition of either Link-N or CKF. Treatment effects were, however, evident with the addition of DEX. For example, MMP1: IL6/TNF + DEX vs. ctrl; log2 fold-change −1.8 [-2.2, −1.4] and OSM/TNF + DEX vs. ctrl; log2 fold-change −0.3 [-0.7, 0.04]. Conclusion: We confirmed that both catabolic models induce changes in osteoarthritis-related proteins. DEX treatment is effective in mitigating the catabolic response in meniscus explant models and may be further explored for its effects in the treatment of meniscus degeneration.</p>}}, author = {{Sjögren, Amanda and Lindblom, Karin and Turkiewicz, Aleksandra and Englund, Martin and Önnerfjord, Patrik}}, issn = {{2665-9131}}, keywords = {{Explant model; Human tissue; Meniscus; Osteoarthritis; Proteomics}}, language = {{eng}}, number = {{3}}, publisher = {{Elsevier}}, series = {{Osteoarthritis and Cartilage Open}}, title = {{Molecular treatments to reduce catabolic effects in human meniscus explant models}}, url = {{http://dx.doi.org/10.1016/j.ocarto.2025.100618}}, doi = {{10.1016/j.ocarto.2025.100618}}, volume = {{7}}, year = {{2025}}, }